Who
Jeffrey K. Tong
Director
Company insider
Files Form 4 as: Director, Septerna; Director and 10% owner, Nurix Therapeutics; VP, Cor. & Product Development, Infinity Pharmaceuticals.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 Jan 2010
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,623 at $0.00 | filing |
| 6 May 2021filed 24 May 2021 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 5 Jan 2010filed 7 Jan 2010 | Infinity Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,440 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.
Related people
Nobody else traded the same names lately.